Tag Archives: ISVHLD

International Symposium on Viral Hepatitis and Liver Diseases

15th International Symposium on Viral Hepatitis and Liver DiseasesThe 15th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD) was held last weekend, June 26 – 28th, in Berlin, Germany. Symposium topics ranged from hep A to hep E treatments and cures  to the history of hepatitis to clinical trial results.

For example, AbbVie, creator of Holkira Pak (generic name: ombitasvir/paritaprevir/ritonavir and dasabuvir), announced that their clinical trial Turquoise-III, testing Holkira Pak without ribavirin, cured 100% of the trial’s 60 patients. The 60 patients all had chronic genotype 1b hep C and compensated liver cirrhosis and were either treatment-naïve (had never tried treatment) or treatment-experienced (failed previous treatment with pegylated interferon and ribavirin). None of the trial’s patients discontinued treatment due to side effects.

A quote from AbbVie’s press release stated: “Genotype 1b represents a large portion of HCV patients globally, as it is the most prevalent sub-genotype, and there is a need to continue to explore additional treatment regimens,” said Jordan J. Feld, M.D., MPH, research director and clinician scientist, Toronto Center for Liver Disease, Toronto, Canada. “The results of TURQUOISE-III are promising, demonstrating that genotype 1b HCV patients with compensated liver cirrhosis have the potential to achieve high response rates with an interferon and ribavirin-free treatment in 12 weeks.”

For more information about hep C treatments please visit PHCN’s Hepatitis C Treatment Information Project or email.